



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

When registering as a guest for the webinar, please be sure to provide first name and family name.

EudraCt – Results Webinar # 6

Presented by Tim Buxton on 24 February 2016

IT Service Strategy Manager, IT Operations

An agency of the European Union





Instructions for sponsors

Frequently asked questions

EudraCT Training page

Timeline & tagging summary



Instructions to sponsors

Main sections

- Timelines
- Status on re-opening of the system
- Review by sponsors of trial results sets within the system
- Posting of results sets due between 31 July 2015 and 13 March 2016
- Posting of results sets due after 13 March 2016
- EMA processes
- Notification processes




Timeline 1 of 2

Date	Observation
13 January 2016	<ul style="list-style-type: none">• Date from which EudraCT - Results system is available• Posting and publication process operational
13 March 2016	<ul style="list-style-type: none">• Results sets falling due after this date (except those for trials categorised as to be posted ≤ 24 months after finalisation of the programming) should comply with the modalities and timing of trial results
13 July 2016	<ul style="list-style-type: none">• Date by which results sets affected by the system closure are to have been posted. Results sets affected by the system closure comprise:<ul style="list-style-type: none">◦ Results sets that were posted, published and removed from public view as of 31 July 2015◦ Results sets that had been posted but not yet published as of 31 July 2015◦ Results sets that fell due in the period that the system was closed (31 July 2015 to 12 January 2016)◦ Results sets that fall due in the two months following re-opening of the system (13 January 2016 to 13 March 2016)
21 December 2016	<ul style="list-style-type: none">• Deadline for submission of summary results for trials categorised as to be posted ≤ 24 months after finalisation of the programming (see document "Trial results: modalities and timing of posting" published on the EudraCT website) - ("≤ 24 mths" trials)

"Affected results sets"



Timeline 2 of 2





Activities necessary to return to normal operation

- Review by sponsors of trial results sets within the system leading to:
 - Correction where needed by the sponsor
 - Authorisation to EMA to restore results sets to public view where no correction is needed
- Submission of data
 - Affected results sets
 - Results for trials categorised as to be posted \leq 24 months after finalisation of the programming



Resources: Schedule of trials assigned to a primary user

User	Name	EudraCT No.	Published	Potential timestamp issues	Potential category issues	Data correction applied	State
Ronald.Held@FictitiousPharma.com	a1a1a1	2013-001234-39	Public	Yes	No	No	FINALIZED
Ronald.Held@FictitiousPharma.com	a1a1a1	2015-001234-27	Public	No	Yes	No	FINALIZED
Ronald.Held@FictitiousPharma.com	a1a1a1	2015-001235-28	Public	No	No	Yes	FINALIZED
Ronald.Held@FictitiousPharma.com	a1a1a1	2011-001234-26	Public	Yes	Yes	Yes	FINALIZED
Ronald.Held@FictitiousPharma.com	a1a1a1	2012-001234-70	Not public	No	No	No	FINALIZED
Ronald.Held@FictitiousPharma.com	a1a1a1	2010-000123-68	Not public	Yes	Yes	No	DRAFT
Ronald.Held@FictitiousPharma.com	a1a1a1	2011-000012-13	Not public	Yes	No	Yes	DRAFT

Note:

- "Yes" means symptoms have been identified that indicated that an error in the relevant classification may have occurred
- "Yes" in the Potential issue columns does **not** mean that there will **always** be such an error present



Trials potentially affected by timestamp issues

Reporting groups

Reporting group 1	Arm 1 of Period 1
Reporting group 2	Arm 2 of Period 1
Reporting group 3	Arm 3 of Period 1

Reporting group 1		Reporting group 2		Reporting group 3	
Subjects analysed: 6		Subjects analysed: 15		Subjects analysed: 24	
<input type="button" value="Edit"/> *		<input type="button" value="Edit"/> *		<input type="button" value="Edit"/> *	
category 1	Count: <input type="text" value="1"/>	category 1	Count: <input type="text" value="4"/>	category 1	Count: <input type="text" value="7"/>
category 2	Count: <input type="text" value="2"/>	category 2	Count: <input type="text" value="5"/>	category 2	Count: <input type="text" value="8"/>
category 3	Count: <input type="text" value="3"/>	category 3	Count: <input type="text" value="6"/>	category 3	Count: <input type="text" value="9"/>

Reporting groups

Reporting group 1	Arm 1 of Period 1
Reporting group 2	Arm 2 of Period 1
Reporting group 3	Arm 3 of Period 1

Reporting group 1		Reporting group 2		Reporting group 3	
Subjects analysed: 6		Subjects analysed: 15		Subjects analysed: 24	
<input type="button" value="Edit"/> *		<input type="button" value="Edit"/> *		<input type="button" value="Edit"/> *	
category 1	Count: <input type="text" value="1"/>	category 1	Count: <input type="text" value="7"/>	category 1	Count: <input type="text" value="4"/>
category 2	Count: <input type="text" value="2"/>	category 2	Count: <input type="text" value="8"/>	category 2	Count: <input type="text" value="5"/>
category 3	Count: <input type="text" value="3"/>	category 3	Count: <input type="text" value="9"/>	category 3	Count: <input type="text" value="6"/>





Trials potentially affected by category issues

Reporting groups

Reporting group 1	Experimental for Arm 1
Reporting group 2	Experimental for Arm 2

Reporting group 1 Subjects analysed: 30 <input type="button" value="Edit"/> *	Reporting group 2 Subjects analysed: 30 <input type="button" value="Edit"/> *
Strain 22/46 - Baseline Test number: <input type="text" value="40"/> confidence interval: 95% <input type="text" value="20"/> to: <input type="text" value="70"/>	Strain 22/46 - Baseline Test number: <input type="text" value="50"/> confidence interval: 95% <input type="text" value="30"/> to: <input type="text" value="90"/>
Strain 22/46 - Post 1st Vaccination number: <input type="text" value="35"/> confidence interval: 95% <input type="text" value="25"/> to: <input type="text" value="69"/>	Strain 22/46 - Post 1st Vaccination number: <input type="text" value="47"/> confidence interval: 95% <input type="text" value="35"/> to: <input type="text" value="77"/>
Strain 22/46 - Post 2nd Vaccination number: <input type="text" value="30"/> confidence interval: 95% <input type="text" value="25"/> to: <input type="text" value="50"/>	Strain 22/46 - Post 2nd Vaccination number: <input type="text" value="45"/> confidence interval: 95% <input type="text" value="30"/> to: <input type="text" value="60"/>
Strain 22/46 - Post 3rd Vaccination number: <input type="text" value="26"/> confidence interval: 95% <input type="text" value="25"/> to: <input type="text" value="28"/>	Strain 22/46 - Post 3rd Vaccination number: <input type="text" value="30"/> confidence interval: 95% <input type="text" value="30"/> to: <input type="text" value="45"/>

Reporting groups

Reporting group 1	Experimental for Arm 1
Reporting group 2	Experimental for Arm 2

Reporting group 1 Subjects analysed: 30 <input type="button" value="Edit"/> *	Reporting group 2 Subjects analysed: 30 <input type="button" value="Edit"/> *
Strain 22/46 - Baseline Test number: <input type="text" value="40"/> confidence interval: 95% <input type="text" value="25"/> to: <input type="text" value="28"/>	Strain 22/46 - Baseline Test number: <input type="text" value="50"/> confidence interval: 95% <input type="text" value="30"/> to: <input type="text" value="45"/>
Strain 22/46 - Post 1st Vaccination number: <input type="text" value="35"/> confidence interval: 95% <input type="text" value="20"/> to: <input type="text" value="70"/>	Strain 22/46 - Post 1st Vaccination number: <input type="text" value="47"/> confidence interval: 95% <input type="text" value="30"/> to: <input type="text" value="90"/>
Strain 22/46 - Post 2nd Vaccination number: <input type="text" value="30"/> confidence interval: 95% <input type="text" value="25"/> to: <input type="text" value="69"/>	Strain 22/46 - Post 2nd Vaccination number: <input type="text" value="45"/> confidence interval: 95% <input type="text" value="35"/> to: <input type="text" value="77"/>
Strain 22/46 - Post 3rd Vaccination number: <input type="text" value="26"/> confidence interval: 95% <input type="text" value="25"/> to: <input type="text" value="50"/>	Strain 22/46 - Post 3rd Vaccination number: <input type="text" value="30"/> confidence interval: 95% <input type="text" value="30"/> to: <input type="text" value="60"/>



Trials where an automated process has been run to eliminate duplicated non-completion or joining reasons

User	EudraCT Number	Period Title	Arm Title	Reason ID 1	Reason ID 2	No. of Subjects
Ronald.Held@FictitiousPharma.con	2013-001234-39	Phase 1 and Phase 2	Phase 2 Arm C - 40 mg Fictilion	15982		8
Ronald.Held@FictitiousPharma.con	2015-001234-27	Phase 1 and Phase 2	Phase 2 Arm A - 20 mg Fictilion	15982		5
Ronald.Held@FictitiousPharma.con	2015-001235-28			22756		2

Type or text	Subject disposition ID	Period	Reason category
Adverse event	5571	Post-Assignment	Not completed reason having type "Other" with same other reason text
Adverse event	5571	Post-Assignment	Not completed reason having type "Other" with same other reason text
106, Consent withdrawn by subject	11872	Pre-Assignment	Not completed Reason whose type is not "Other" (but from the specified list in R_TERMS table)



Resources: Release notes for version 10.2.1.0

- Summary of release 10.2.1.0
 - Major items fixed in release 10.2.1.0
 - Known issue in release 10.2.1.0
- Full release contents – Issues fixed
- Known errors
- New Validation Violation Messages (for XML upload) in EudraCT - Results 10.2.1.0
- Additional information
- Installation steps deviating from the deployment guide



Known error: Reporting group display order

Arm title	Arm description	No. Started	No. Completed	Options
AAAAA		6	3	Edit Delete
BBBBB		5	2	Edit Delete

Baseline characteristics >
Age continuous values

Overview

Characteristic title:
Age Continuous

Units:
years

Description:

Reporting groups

Reporting group 1	Reporting group 2
subjects: 6*	subjects: 5*
arithmetic mean: 57.2	arithmetic mean: 64.6
standard deviation: 13.8	standard deviation: 9.9

Adverse events reporting groups

Reporting group title	Options
BBBBB	Edit Delete
AAAAA	Edit Delete



Processes

- For results sets finalised as at 31 July 2015
 - Restore status and return to public view ◆
 - Create new version to correct data affected by the system ◆ ◆
 - For results sets in draft, or not assigned as at 31 July 2015
 - Submit in compliance with revised timelines¹ ◆ ◆
-
- Submit in accordance with standard timelines ◆ ◆

¹Where, due to unavailability of the system, sponsors are or have been unable to comply with the standard timelines

- ◆ Review
- ◆ Correct
- ◆ Notify EMA



Restore status and return to public view process

Notifications

- Sponsor notification to EMA: Finalized results set in the system is correct
- EMA notification to sponsor: Status of finalized results set is restored

Published messages:

- Messages removed:
 - *“Removed from public view”*
 - *“These results have been removed from public view whilst they are reviewed and may need to be corrected before being returned to public view”*



Outcome of restore status and return to public view (section 7.1 Instructions to sponsors)

[< Back to search results](#)

No system error; no highlighted tag

[Download PDF](#)

Clinical Trial Results:



Summary	
EudraCT number	
Trial protocol	
Global end of trial date	20 Mar 2013
Results information	
Results version number	v1(current)
This version publication date	01 Feb 2016
First version publication date	31 Jul 2015
Other versions	

[Trial Information](#)

[Subject Disposition](#)

[Baseline Characteristics](#)

[End Points](#)

[Adverse Events](#)

[More Information](#)

- Data reinstated as it was before system made unavailable
- Note date of re-publication of v1(current) – restoration process
- Original publication date maintained

[Collapse all](#) [Expand all](#)



Tagging of superseded versions of results sets that included affected data

Notifications

- Sponsor notification to EMA: New version of finalized results set containing corrected data
- EMA notification to sponsor: Superseded versions tagged

Published messages

- Messages removed:
 - *“Removed from public view”*
 - *“These results have been removed from public view whilst they are reviewed and may need to be corrected before being returned to public view”*
- New message:
 - *“Due to a system error, the data reported in version [v1] is not correct and has been removed from public view”*



Outcome of tagging of superseded versions of affected data (s7.2 Instructions to sponsors)

[< Back to search results](#)

[Download PDF](#)

System error, therefore highlighted tag

Clinical Trial Results:



Due to a system error, the data reported in v1 and v2 are not correct and have been removed from public view.

Summary	
EudraCT number	
Trial protocol	
Global end of trial date	27 May 2013
Results information	
Results version number	v3(current)
This version publication date	31 Jan 2016
First version publication date	25 Dec 2014
Other versions	v1 (removed from public view) , v2 (removed from public view)
Version creation reason	<ul style="list-style-type: none"> Correction of full data set Correction adverse events.

- [Trial Information](#)
- [Subject Disposition](#)
- [Baseline Characteristics](#)
- [End Points](#)
- [Adverse Events](#)
- [More Information](#)

- Data as it was before system made unavailable removed from public view
- This version is corrected data - v3(current) – restoration process
- Original publication date maintained

[Collapse all](#) [Expand all](#)



Outcome: No tagging of superseded versions of affected data (s7.2 Instructions to sponsors)

[< Back to search results](#)

[Download PDF](#)

No system error; no highlighted tag

Summary	
EudraCT number	[REDACTED]
Trial protocol	[REDACTED]
Global end of trial date	
Results information	
Results version number	v2(current)
This version publication date	05 Feb 2016
First version publication date	24 Jul 2015
Other versions	v1
Version creation reason	<ul style="list-style-type: none"> Correction of full data set <p>Updated results entries to be consistent with results on Clinicaltrials.gov after NIH comments.</p>

[Trial Information](#)
[Subject Disposition](#)
[Baseline Characteristics](#)
[End Points](#)
[Adverse Events](#)
[More Information](#)

- This version is data amended for reasons unrelated to system error
- Data as it was before system made unavailable restored to public view
- Original publication date maintained

[Collapse all](#) [Expand all](#)



Tagging of results sets submitted in compliance with revised timelines

Notifications

- Sponsor notification to EMA: Results set submitted in compliance with revised timelines
- EMA notification to sponsor: Results set submitted in compliance with revised timelines tagged

Published message

- New message:
 - *“Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines”*



Outcome of tagging of results - compliance with revised timelines (s7.3 Instructions for sponsors)

[< Back to search results](#)

[Download PDF](#)

System unavailability, therefore highlighted tag

Clinical Trial Results:



Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.

Summary	
EudraCT number	
Trial protocol	
Global end of trial date	01 Apr 2015
Results information	
Results version number	v1(current)
This version publication date	29 Jan 2016
First version publication date	29 Jan 2016
Other versions	

- Submission due within 6 months of the global end trial date
- This version v1(current) is affected by the dates the system was unavailable

[Trial Information](#)
[Subject Disposition](#)
[Baseline Characteristics](#)
[End Points](#)
[Adverse Events](#)
[More Information](#)



Communications: Formal notifications only

- For the formal notifications outlined in the Instructions for sponsors (section 8); and
- Communications clarifying queries in relation to notifications submitted

Use: EudraCT-R@ema.europa.eu



Communications: **All** other queries related to EudraCT – Results and this exercise

From 1 March 2016

- New self-service portal for all technical IT requests and issues in relation to EMA supported IT systems (<https://servicedesk.ema.europa.eu/>).
 - Replaces functional email addresses on EMA webpages
 - Use EudraCT username & password to log in to portal
 - If not registered for EudraCT or one of most other EMA hosted systems, create a new account (automated process)
- Transition (1 February to 1 March 2016)
 - Incidents or service requests logged before 1 February managed to closure using previous process
 - Existing support email addresses will be monitored
 - incidents or service requests transferred into the new portal
 - automated response including a link to the new portal



Instructions for sponsors

Frequently asked questions

EudraCT Training page

Timeline & tagging summary



Principles of user management: EudraCT - Results

- Initial assignment of primary user by EMA following sponsor request
- User management during drafting under the control of the sponsor
- Both a primary user and a backup user should be assigned to each trial
 - Both have user assignment rights – risk reduction for leavers
- Where a user leaves a company
 - Primary/backup user to remove assignments to trials
 - EMA to be informed



User management scenarios

1. Primary user leaves suddenly; Backup user assigned

- Backup user removes the assignment to the primary user
- Backup user assigns self to the primary user role
- Primary user assigns new backup user
- Sponsor notifies EMA that the primary user is no longer with the company¹
- EMA disables that user's access to EudraCT - Results

2. Primary user leaves suddenly; No backup user assigned

- Sponsor contacts EMA¹ to
 - Notify EMA that primary user is no longer with the company
 - Request assignment of the trial to a EudraCT – results user as primary user
- EMA removes primary user from the trial & disables access to EudraCT – Results
- EMA assigns the new primary user
- Primary user assigns a new backup user



Tagging of results sets submitted in compliance with revised timelines

It will only be necessary to tag results sets that are actually submitted beyond the deadline in consequence of the unavailability of the system. Examples:

Global trial end date: 11 December 2014	Global trial end date: 15 July 2015
Due date: 11 December 2015	Due date: 15 July 2016
Submitted date: 18 May 2016	Submitted date: 30 June 2016
Tagging appropriate	No tagging needed – compliant with standard timelines



Instructions for sponsors

Frequently asked questions

EudraCT Training page

Timeline & tagging summary



EudraCT Home page

https://eudract.ema.europa.eu/

File Edit View Favorites Tools Help

Suggested Sites VMware Service Manager Web Slice Gallery

EudraCT

Home Help FAQ Contact Us European Clinical Trials Database

Access to EudraCT
EudraPharm EU CTR
Protocol documentation
Results documentation
Technical documentation
Training
Statistics
NCA contacts
Links

Update: 13 January 2016

The system has been made available on 13 January 2016. The summary results will be gradually made available for public access from that date, once the information has been reviewed and verified. Full access for sponsors has also been restored from that date.

In the context of clinical trial sponsors' or PIP addressees' inability to meet regulatory reporting timeframes while the system was offline: The new deadline for submission for all summary results affected by the period that the system was offline will be 13 July 2016, allowing a period of six months from the date of re-opening of the system. Affected results are those whose submission deadline fell due during the period that the system was offline, as well as those whose submission deadline falls within a period of two months from the re-opening date.

In addition, for trials categorised as to be posted ≤ 24 months after finalisation of the programming (see document "Trial results: modalities and timing of posting"), the deadline for submission of summary results will be 21 December 2016, being five months from the current deadline in July 2016.

The issues causing errors in data recording have been fixed. These are described in the [release notes](#) (see "timestamp" and "category" issues). The results presented are correct. However, the issue that causes the order of display of reporting groups and results to differ through the results set has not been addressed. The reporting groups and results themselves are correct; it is only the display order that is affected.

Welcome to the community clinical trial public home page

The European Medicines Agency has launched a new version of the European Clinical Trials Database (EudraCT). This new version, EudraCT V10, marks the final step of a process through which summary clinical trial results will be made publicly available through the EU Clinical Trials Register (EU CTR).

Sponsors' representatives are recommended to register with EudraCT in order to become results users and before they can log into EudraCT. The registration process is described in the help and is accessed on the [login](#) page.



EudraCT Training page

File Edit View Favorites Tools Help

Suggested Sites VMware Service Manager Web Slice Gallery

[Home](#) [Help](#) [FAQ](#) [Contact Us](#)

European Clinical Trials Database

Access to EudraCT

[EudraPharm EU CTR](#)[Protocol documentation](#)[Results documentation](#)[Technical documentation](#)[Training](#)[Statistics](#)[NCA Contacts](#)[Links](#)


EudraCT Training

The EudraCT result training environment can be found [here](#). The training application is aimed at representatives of sponsors and sponsor-investigators who want to familiarise themselves, and get a better understanding in the preparation and posting of trials results in EudraCT.

Training on EudraCT results

- [Getting started with EudraCT to prepare and post results](#)
- [Managing users and preparing results in EudraCT](#)
- [Questions from the V9 workshop - 30 October 2013](#)
- [Questions from the V9 workshop - 15 November 2013](#)
- [Questions from the V9 workshop - 20 November 2013](#)
- [EudraCT V10 - Q&A for 19 Sept 2014 session](#)
- [EudraCT V10 - Q&A for 30 Oct 2014 session](#)
- [EudraCT V10 - Q&A for 16 December 2014 session](#)
- [Training session for stakeholders on results EudraCT V10](#)
- [Presentation from the EudraCT - Results Webinar on 20 January 2016](#)
- [Questions from the EudraCT - Results Webinar on 20 January 2016 \(revised\)](#)
- [Presentation from the EudraCT - Results Webinar on 27 January 2016](#)
- [Questions from the EudraCT - Results Webinar on 27 January 2016](#)
- [Presentation from the EudraCT - Results Webinar on 03 February 2016](#)
- [Questions from the EudraCT - Results Webinar on 03 February 2016](#)



Last updated February 2016
 European Medicines Agency © 1995-2016
 Application hosted on behalf of the European Commission <http://ec.europa.eu>
 For technical support, visit the EMA Service Desk portal: <https://servicedesk.ema.europa.eu>
 For urgent technical matters, telephone: +44 (0)20 3660 8520 
 30 Churchill Place, Canary Wharf, London E14 5EU



Instructions for sponsors

Frequently asked questions

EudraCT Training page

Timeline & tagging summary



Timeline & tagging summary

Due date for posting ¹	Original posted date ²	Correction needed ³	Deadline now applicable ⁴	Date actually posted ⁵	Applicable tag(s) ⁶	Comment
21/07/2015	06/07/2015	No	13/07/2016	N/A	N/A	Results as originally posted require no correction. Restored to public view with no tags, (See slide 14)
21/07/2015	08/07/2015	Yes	13/07/2016	08/07/2016	1,2	New, corrected version posted. Superseded version tagged (1) and remains removed from public view. New version tagged (2) (See slide 16)
21/07/2015	18/07/2015	Yes ⁷	N/A	19/07/2016	N/A	Results as originally posted require no correction for system errors. Restored to public view with no tags. New version published as usual - no tags (See slide 17)
08/10/2015	N/A	No	13/07/2016	18/05/2016	3	Results affected by system closure. Posted with tag 3. (See slide 19)
08/10/2015	N/A	Yes	13/07/2016	19/05/2016	3	Results affected by system closure. Posted with tag 3. No other tagging as no previous versions posted. (See slide 19)
17/02/2016	N/A	No	13/07/2016	12/02/2016	N/A	Results posted in accordance with originally applicable deadline. No tag.
17/02/2016	N/A	Yes	13/07/2016	16/06/2016	3	Results affected by system closure. Posted with tag 3. No other tagging as no previous versions posted. (See slide 19)
07/04/2016	N/A	No	07/04/2016	30/03/2016	N/A	Results posted in accordance with applicable deadline. No tag.
07/04/2016	N/A	Yes	07/04/2016	04/04/2016	N/A	Results posted in accordance with applicable deadline. No tag. Note no previous versions posted.
21/07/2016	N/A	No	21/12/2016	30/06/2016	N/A	Results posted in accordance with originally applicable deadline. No tag.
21/07/2016	N/A	Yes	21/12/2016	23/11/2016	3	Results affected by system closure. Posted with tag 3. No other tagging as no previous versions posted. (See slide 19)



Timeline & tagging summary

Footnotes 1 of 2

1. Due date for posting calculated from the “Trial results: Modalities and timing of posting” document
2. Original date of posting of version finalized in EudraCT – Results as of 31 July 2015
3. If correction needed in consequence of system errors in EudraCT: Yes (except as described in footnote 7)
4. The new deadlines for all summary results affected by the period that the system was offline; or the deadlines for results calculated from the “Trial results: Modalities and timing of posting” document for summary results not affected



Timeline & tagging summary

Footnotes 2 of 2

5. Date summary results posted by the sponsor in relation to the deadlines described in note 4.
6. Public notes to be applied (tags)
 1. "Due to a system error, the data reported in this version is not correct and has been removed from public view"
 2. "Due to a system error, the data reported in version [v1] is not correct and has been removed from public view"
 3. "Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines"
7. This instance of "Yes" relates to corrections to the data needed for reasons unrelated to system errors